Wegovy Insurance Coverage

Wegovy's list price sits around $1,349 per month, which means insurance coverage usually decides whether the prescription is realistic for most people. The frustrating part is that "insurance" isn't one answer. Two people on similar plans can get very different decisions because employer benefit design — not the insurer's logo — controls whether anti-obesity medications are included.

This guide walks through what to check before your first appointment, how prior authorization typically works, and what your options look like if you receive a denial. Pricing and policies shift frequently; always verify current numbers with your pharmacy and your benefits administrator.

What it costs without help

Without coverage, the Wegovy list price is roughly $1,349 per package. Most cash-paying patients don't pay that number at retail — Novo Nordisk's NovoCare Pharmacy currently offers self-pay pricing around $349 per month across all dose strengths for eligible patients without insurance, and limited-time introductory pricing has been as low as $199 per month for new patients on lower doses.

Pharmacy variance also matters. The same prescription can ring up at very different prices at chain versus independent pharmacies, and discount cards such as GoodRx sometimes shave off a portion. Call two or three pharmacies in your area for the same dose before you commit — and confirm directly with the pharmacy on the day you plan to fill, since these prices change.

How to check coverage before you start

When you make those calls, write down the date, the representative's name, and the reference number. Coverage decisions are appealable, and a paper trail helps your provider's office push back if the first answer doesn't match what you find in the formulary.

Prior authorization: what plans usually require

Even when a plan covers Wegovy, prior authorization is almost always required. The exact criteria vary, but most commercial plans look for the same core documentation: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Some plans require documented participation in a structured weight management program for several months before they'll approve the medication.

Your prescribing clinician submits the PA on your behalf, but you can speed things up by bringing the right inputs to the visit: recent height and weight, blood pressure, recent labs (A1C, lipid panel), and a brief history of prior weight-loss attempts. If your plan requires step therapy, ask whether you'll need to try (and document) a different medication first before Wegovy is approved.

Decisions usually come back within a few business days, sometimes a few weeks. If approved, the PA is typically valid for a year, after which a renewal with updated weight and progress data is required.

If insurance denies it

A denial isn't the end of the conversation. Most plans offer at least one level of internal appeal, and many states have external review processes after that. Common denial reasons include missing BMI documentation, lack of comorbidity diagnosis on file, no record of prior weight-loss attempts, or a plan exclusion of anti-obesity medications entirely. The first step is identifying which reason applies, because the response differs.

If the denial is for missing documentation, your provider can resubmit with the right records. If it's for failed step therapy, you may need to document a prior trial of phentermine, orlistat, or another listed alternative. If the plan flatly excludes anti-obesity drugs, an appeal won't succeed — that's a benefit design decision, and your best paths are the manufacturer's self-pay program, a switch to an employer plan that includes coverage during open enrollment, or pursuing Wegovy through the Medicare GLP-1 Bridge if you become Medicare-eligible.

For appeals that do have a chance, ask your provider to write a letter of medical necessity that cites your BMI, comorbidities, prior attempts, and the clinical guidelines supporting GLP-1 therapy. Keep your own copies of every submission.

Medicare, Medicaid, and the GLP-1 Bridge

Historically, Medicare Part D did not cover anti-obesity medications. That changes in mid-2026: CMS has announced the Medicare GLP-1 Bridge, a demonstration program running July 1, 2026 through December 31, 2027, that provides coverage of Wegovy (and select other GLP-1s) for eligible Part D beneficiaries at a copay around $50 per month. Eligibility generally requires a BMI of 27 or higher with a qualifying condition such as cardiovascular disease or prediabetes, or a BMI of 35 or higher. The exact rules and timeline may change — confirm with your Part D plan and CMS resources before counting on this pathway.

Medicaid coverage continues to vary state by state. Some states cover Wegovy for obesity, others only for cardiovascular risk reduction in patients with established disease, and others not at all. Your state Medicaid agency or your managed care plan can confirm.

Common questions

Keep exploring

Browse all GLP-1 guides.